

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Botanix Pharmaceuticals Limited
ACN	009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stewart Washer
Date of last notice	3 December 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (Including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Dr Stewart James Washer + Dr Patrizia Derna Washer <The Washer Family A/C> - Dr Washer is a trustee and beneficiary of the trust.
Date of change	27 February 2025
No. of securities held prior to change	<p>Dr Stewart James Washer + Dr Patrizia Derna Washer <The Washer Family A/C> - Dr Washer is a trustee and beneficiary of the trust.</p> <ul style="list-style-type: none"> • 654,884 Fully Paid Ordinary Shares • 5,000,000 Unlisted Options exercisable at \$0.102 each, expiring 22 March 2025 • 333,333 Performance Rights (expiring 30 November 2026) • 3,000,000 Performance Rights (expiring 2 December 2029) <p>Mal Washer Nominees Pty Ltd - Dr Washer is a Director.</p> <ul style="list-style-type: none"> • 1,515,151 Fully Paid Ordinary Shares

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Ordinary fully paid shares and unlisted Options exercisable at \$0.102 each, expiring 22 March 2025
Number acquired	3,990,099 ordinary fully paid shares
Number disposed	5,000,000 unlisted Options exercisable at \$0.102 each, expiring 22 March 2025
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil – issued in accordance with the cashless exercise facility under the terms and conditions of the Company's Employee Awards Plan.
No. of securities held after change	<p>Dr Stewart James Washer + Dr Patrizia Derna Washer <The Washer Family A/C> - Dr Washer is a trustee and beneficiary of the trust.</p> <ul style="list-style-type: none"> • 4,644,983 Fully Paid Ordinary Shares • 333,333 Performance Rights (expiring 30 November 2026) • 3,000,000 Performance Rights (expiring 2 December 2029) <p>Mal Washer Nominees Pty Ltd - Dr Washer is a Director.</p> <ul style="list-style-type: none"> • 1,515,151 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of fully paid ordinary shares on exercise of options in accordance with the terms of the Company's Employee Awards Plan.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.